Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could replace bone marrow biopsy for myelofibrosis patients

NCT ID NCT06164561

Recruiting now Diagnosis Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special type of PET/MRI scan, using a tracer called 18F-FAPI, can accurately diagnose and track myelofibrosis. Researchers will compare the scan results with standard bone marrow biopsies in 57 patients. If the scan works well, it could offer a less painful way to monitor the disease over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-FAPI (a radioactive tracer used in PET/MRI imaging)
What this could lead to
If successful, this could provide a less invasive way to diagnose and monitor myelofibrosis, potentially replacing some bone marrow biopsies.
What could go wrong
This is an early observational study with only 57 participants, so results may not apply to everyone. The imaging method is still experimental and not yet proven to be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.